SPYH:F:F-SSgA SPDR ETFs Europe II Public Limited Company - SPDR MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 215.2

Change

-2.10 (-0.97)%

Market Cap

USD 0.64B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.26 (+0.97%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.59 (+1.17%)

USD 115.04B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.24 (+1.10%)

USD 83.57B
SXR8:F iShares Core S&P 500 UCITS ETF..

+5.28 (+1.06%)

USD 80.45B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.54 (+0.99%)

USD 76.57B
EUNL:F iShares Core MSCI World UCITS ..

+0.93 (+1.04%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

+2.95 (+1.29%)

USD 58.19B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.16 (+1.06%)

USD 56.18B
VUSA:F Vanguard Funds Public Limited ..

+0.93 (+1.04%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.92 (+1.04%)

USD 49.95B

ETFs Containing SPYH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.36% 70% C- 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.36% 68% D+ 62% D
Trailing 12 Months  
Capital Gain 6.51% 50% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.51% 48% F 53% F
Trailing 5 Years  
Capital Gain 62.19% 83% B 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.19% 83% B 64% D
Average Annual (5 Year Horizon)  
Capital Gain 8.72% 79% B- 74% C
Dividend Return 8.72% 78% C+ 68% D+
Total Return N/A 66% D+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 8.58% 65% D 84% B
Risk Adjusted Return 101.60% 99% N/A 97% N/A
Market Capitalization 0.64B 66% D+ 53% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike